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Dear Editor,
In the current clinical practice, minimal criteria to define
thrombotic thrombocytopenic purpura (TTP) are the presence
of signs of microangiopathic haemolytic anaemia and low
platelet (PLT) count [1]. TTP relapses (20–50 % of cases)
are defined as the recurrence of acute TTP symptoms 30 days
after the first episode, while exacerbations occur within
30 days [2]. We here report on an atypical case of acquired
TTP where minimal criteria were met only after many recur-
rent macrovascular ischemic events.
A 42-year old Caucasian woman with a history of
coronary and cerebral ischemic events was admitted on
June 2013, following a recurrent transient ischemic at-
tack (TIA). She had severe anaemia and thrombocyto-
penia with laboratory signs of intravascular haemolysis
and mild renal impairment. In her past medical history,
recurrent ischemic events occurred from 2008 to 2012,
without known risk factors and regardless of treatment.
The patient was treated with acetyl salicylic acid
(100 mg daily) after the first ischemic event (stroke,
in 2008) plus anticoagulation with warfarin after the
third stroke (in 2010), with a good compliance . Screen-
ing for autoimmune disease, Factor V Leiden and Factor
II (G20210A) gene mutations and circulating anticoagu-
lants were normal. Blood cell count and peripheral
blood smear did not show any significant abnormalities
in the past, without evidence of schistocytes; a slight
decrease in PLT count (92×109/L) was observed only
once (in 2012), at that time, ADAMTS13 activity
(ADAMTS-13: AC) was 65 %. At the current admis-
sion, ADAMTS-13: AC was 6 %, inhibitors were at
high titer (2 Bethesda Units, BU). A genetic test for
Upshaw-Schülman syndrome was normal. Therapeutic
plasma exchange (TPE) and prednisone (1 mg/kg body
weight) treatment was started and maintained until clin-
ical and haematological remission [3]. TPE (Gambro®,
Italy) was performed daily for 3 weeks with an increase
of ADAMTS13: AC to 50 %. TTP exacerbated after
10 days, it was well controlled with weekly rituximab
(375 mg/m2 body surface), for 4 weeks. A relapse oc-
curred after 37 days with the patient presenting seizures:
ADAMTS-13: AC, which was 54 % after the last treat-
ment, had decreased to 6 %. A second course of weekly
rituximab, followed by maintenance with azathioprine
(50 mg twice daily for 10 days, then 50 mg, daily)
was followed by clinical and haematological remission.
Rituximab was re-administered for its previous rapid
efficacy and to prevent further complications [4]. The
patient is alive and free from recurrences for 18 months;
azathioprine maintenance is still on course. ADAMTS-
13: AC is monitored every 4 months, and it ranges
from 45 to 51 %; inhibitors are no longer detectable.
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We hypothesize that the disease occurred in 2008, with
a chronic relapsing behaviour and a more acute phase
only in 2013. Ten similar cases have been reported
[5–10] (Table 1). In atypical TTP recurrences, symp-
toms mainly guide treatment at recurrence. Most of the
described cases recovered after the administration of ri-
tuximab or immunosuppressive agents.
Our case was especially atypical because it became mani-
fested only after years during which even minimal criteria for
TTP diagnosis were not met and ADAMTS13: AC was
normal.
When macrovascular ischemic events are not accompanied
by anaemia or thrombocytopenia, TTP is rarely taken into
account.
However, TTP should be considered even with only slight
laboratory and haematological abnormalities.
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